A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon alpha-2a (Pegasys)11/01/2011 - 12/31/2014 (PI)
Gilead Sciences, Inc.
A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon alpha-2a (Pegasys)11/01/2011 - 12/31/2014 (PI)
Gilead Sciences, Inc.
A Study to Describe the Safety and Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics with Chronic Hepatitis B Virus (HBV) Infection who are Nucleoside-Naive10/17/2006 - 10/16/2008 (PI)
Bristol-Myers Squibb
A Randomized, Placebo Controlled, Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of NOV-205 in Chronic Viral Hepatitis C Subjects (Genotype 1) who have failed Treatment with Pegylated Interferon plus Ribavirin01/23/2007 - 01/22/2008 (PI)
Novelos Therapeutics, Inc.
Phase II Study Of Long Term Peg Intron Fpr Patients Who Have Failed to Respond to Rebetron/Interferon with Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C.05/11/2001 - 05/31/2005 (PI)
Schering Corporation
Evaluating the Erythropoietic Response to Anemia in HCV01/01/2002 - 12/31/2003 (PI)
Ortho Biotech Inc
Comparison of PEG Interferon Alfa 2b Plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects12/01/2001 - 11/30/2003 (PI)
Integrated Therapeutics Group
A Prospective, Randomized, Multicenter, Open Label Comparative Safety Study of Pegasys vs. Pegasys Plus Ribavirin Treatment vs. a Twelve Treatment Delay in Patients with Chronic Hepatitis C02/06/2001 - 12/31/2002 (PI)
Roche Laboratories Inc
A Randomized, Partially Blinded, Multicenter, Phase II Study Investigating the Efficacy and Safety of Pegasys and Pegasys with Ribavirin in Treatment Naive Patients with Chronic Hepatitis C Coinfected with Human Immunodeficiency Virus01/18/2001 - 01/31/2002 (PI)
Roche Laboratories Inc